Journal article icon

Journal article

comBO: A combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disorders

Abstract:
The bone marrow is the primary site of blood and immune cell production in postnatal life. Current human models do not capture lympho-myeloid hematopoiesis and the stromal diversity needed for lifelong blood and immune maintenance. Here, we introduce comBO (combined bone and lympho-myeloid bone marrow organoid), a scalable induced pluripotent stem cell (iPSC)-derived system that generates osteolineage, vascular, lymphoid, and myeloid compartments within a single organoid. Developed under physioxia in granular microgel scaffolds, comBOs improve scalability and reproducibility and sustain long-term lympho-myeloid potential in serial organoid re-seeding assays. Incorporating healthy or malignant donor cells produces "chimeroids" that model physiological and pathological states. Using multiple myeloma as an exemplar, comBOs recapitulate niche remodeling and identify macrophage inhibitory factor (MIF) signaling as a disease driver. MIF inhibition reduces inflammation and myeloma proliferation, highlighting its therapeutic potential. comBOs offer a physiologically faithful bone marrow platform for disease modeling and therapeutic discovery in translational hematology and immunology.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1016/j.stem.2026.01.010

Authors

More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Radcliffe Department of Medicine
Sub department:
RDM-Weatherall Inst of Molecular Medicine
Oxford college:
Lady Margaret Hall
Role:
Author
ORCID:
0009-0008-9114-8743
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Radcliffe Department of Medicine
Sub department:
RDM-Weatherall Inst of Molecular Medicine
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Radcliffe Department of Medicine
Sub department:
RDM-Weatherall Inst of Molecular Medicine
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Radcliffe Department of Medicine
Sub department:
RDM-Weatherall Inst of Molecular Medicine
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Radcliffe Department of Medicine
Sub department:
RDM-Weatherall Inst of Molecular Medicine
Role:
Author


More from this funder
Funder identifier:
https://ror.org/029chgv08
Grant:
323265/Z/24/Z
218649/Z/19/Z
216632/Z/19/Z
More from this funder
Funder identifier:
https://ror.org/054225q67
Grant:
RCCCSF-Nov21\100004
More from this funder
Funder identifier:
https://ror.org/03x94j517
Grant:
MC_UU_00029/7
MR/X012743/1
MC_UU_12025
G0902418
More from this funder
Funder identifier:
10.13039/501100000265
Grant:
MC_UU_00029/7
More from this funder
Funder identifier:
https://ror.org/01e473h50


Publisher:
Elsevier
Journal:
Cell Stem Cell More from this journal
Volume:
33
Issue:
3
Pages:
421-437
Place of publication:
United States
Publication date:
2026-02-23
Acceptance date:
2026-01-21
DOI:
EISSN:
1875-9777
ISSN:
1934-5909
Pmid:
41734765


Language:
English
Pubs id:
2382599
Local pid:
pubs:2382599
Source identifiers:
W7131088910
Deposit date:
2026-04-28
ARK identifier:

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP